KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Inventory (2017 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Inventory for 10 consecutive years, with $5.6 million as the latest value for Q1 2026.

  • For Q1 2026, Inventory fell 51.69% year-over-year to $5.6 million; the TTM value through Mar 2026 reached $5.6 million, down 51.69%, while the annual FY2025 figure was $10.0 million, 19.69% down from the prior year.
  • Inventory hit $5.6 million in Q1 2026 for Ionis Pharmaceuticals, down from $10.0 million in the prior quarter.
  • Across five years, Inventory topped out at $30.3 million in Q1 2024 and bottomed at $5.6 million in Q1 2026.
  • Average Inventory over 5 years is $18.4 million, with a median of $20.6 million recorded in 2022.
  • Year-over-year, Inventory surged 68.15% in 2024 and then plummeted 70.47% in 2025.
  • Ionis Pharmaceuticals' Inventory stood at $22.0 million in 2022, then tumbled by 66.23% to $7.4 million in 2023, then soared by 68.15% to $12.5 million in 2024, then fell by 19.69% to $10.0 million in 2025, then tumbled by 44.7% to $5.6 million in 2026.
  • According to Business Quant data, Inventory over the past three periods came in at $5.6 million, $10.0 million, and $10.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.